stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Gross margin
Legend Biotech Corporation Sponsored ADR's gross margin over the twelve months to 30 June 2026 was 56.6%, down 3.8 percentage points from fiscal 2025 (60.3%). Over the past ten years it has ranged from 0.00% (fiscal 2017) to 100.0% (fiscal 2021); the current reading is higher than 44% of that period. That is below the Biotechnology industry median of 68.5% and in line with the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 60.3% | (2.26) |
| FY2024 | 62.6% | 13.18 |
| FY2023 | 49.4% | 5.28 |
| FY2022 | 44.1% | (55.86) |
| FY2021 | 100.0% | 0.00 |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 100.00 |
| FY2017 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 64.5% | 22.19 |
| Mar 2026 | 42.4% | (17.35) |
| Dec 2025 | 59.7% | 2.04 |
| Sep 2025 | 57.7% | (3.92) |
| 23 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RLAY Relay Therapeutics, Inc. compare | 100.0% |
| CRSP CRISPR Therapeutics AG compare | 100.0% |
| DNTH Dianthus Therapeutics, Inc. compare | 100.0% |
| TVTX Travere Therapeutics, Inc. compare | 98.5% |
| LEGN Legend Biotech Corporation Sponsored ADR | 56.6% |
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| ERAS Erasca, Inc. compare | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| Biotechnology industry median | 68.5% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement